Please assess the completion status of the following clinical trial:

Trial Title: Study of Colchicine to Treat and Prevent Recurrent Pericarditis (First Episode)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with the first attack of recurrent pericarditis~* Age≥ 18 years~* Informed consent~Exclusion Criteria:~* Suspected neoplastic, tuberculous, or purulent etiology~* Known severe liver disease and/or elevated transaminases \>1.5 times the upper limit of normality~* Serum creatinine \>2.5 mg/dl~* Serum creatine kinase (CK) over the upper limit of normality or known myopathy~* Known gastrointestinal or blood disease~* Pregnant or lactating women or women not protected by a contraception method~* Known hypersensibility to colchicine~* Treatment with colchicine at enrolment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator
- Colchicine (Type: EXPERIMENTAL): Colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 6 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).